5 Stocks Pushing The Drugs Industry Downward

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 156 points (-1.1%) at 14,709 as of Monday, April 15, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 426 issues advancing vs. 2,527 declining with 106 unchanged.

The Drugs industry currently sits down 2.11 versus the S&P 500, which is down 1.29. On the negative front, top decliners within the industry include Regeneron Pharmaceuticals ( REGN), down 2.75, Shire ( SHPG), down 2.13, Amgen ( AMGN), down 1.70, Biogen Idec ( BIIB), down 1.50 and Eli Lilly and Company ( LLY), down 0.71.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry lower today:

5. Forest Laboratories ( FRX) is one of the companies pushing the Drugs industry lower today. As of noon trading, Forest Laboratories is down $1.24 (-3.3%) to $36.75 on average volume Thus far, 1.0 million shares of Forest Laboratories exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $36.75-$37.89 after having opened the day at $37.80 as compared to the previous trading day's close of $37.99.

Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products primarily in the United States and Europe. Forest Laboratories has a market cap of $10.2 billion and is part of the health care sector. The company has a P/E ratio of 89.1, above the S&P 500 P/E ratio of 17.7. Shares are up 7.6% year to date as of the close of trading on Friday.

TheStreet Ratings rates Forest Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full Forest Laboratories Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you liked this article you might like

Cramer: There Are Some Bargains Out There

Cramer: There Are Some Bargains Out There

Teva, Actavis, Other Generic Drugmakers May Be on Acquisition Trail

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

Why Endo International Can Deliver Solid Rewards With Minimal Risk

3 Stocks Driving The Health Care Sector Higher